Browse
Submit Data
Databases
API
Help

Dataset Information

11 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

ABSTRACT: The objective is to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to imatinib.

DISEASE(S): Gastro Intestinal Stromal Tumor,Gastrointestinal Stromal Tumors

PROVIDER: 2118321 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

Project description:Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

| 2065554 | ecrin-mdr-crc

Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate

Project description:RATIONALE: Surgery may remove residual disease in patients with gastrointestinal stromal tumor that is responding to imatinib mesylate. It is not yet known whether surgery is more effective than continued imatinib mesylate in treating patients with metastatic gastrointestinal stromal tumor. PURPOSE: This randomized phase III trial is studying giving imatinib mesylate therapy together with surgery to see how well it works compared with imatinib mesylate alone in treating patients with metastatic gastrointestinal stromal tumor that is responding to imatinib mesylate.

| 2076430 | ecrin-mdr-crc

ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor

Project description:siRNA knock-down of ZNF genes determined to impact gastrointestinal stromal tumor response to imatinib were used to determine functional significance of ZNFs and identify key targets related to imatinib resistance.

2013-08-01 | GSE40080 | GEO

ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor

2013-08-01 | E-GEOD-40080 | biostudies-arrayexpress

microRNA expression signatures of imatinib-treated and non-treated gastrointestinal stromal tumors

2015-08-01 | GSE63159 | GEO

Small RNA expression signatures of gastrointestinal stromal tumors: associations to imatinib resistance and patient outcome

2013-04-10 | GSE45901 | GEO

Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence

Project description:The objective is to compare the efficacy and safety of masitinib at 4.5 mg/kg/day to placebo in the treatment of patients with localized, primary gastrointestinal stromal tumor (GIST) after complete surgery and with high risk of recurrence.

| 2156727 | ecrin-mdr-crc

microRNA expression signatures of imatinib-treated and non-treated gastrointestinal stromal tumors

Project description:We performed microRNA expression profiling in a series of fresh-frozen neoadjuvantly imatinib-treated and non-treated gastrointestinal stromal tumors (GIST), using a microarray approach. Significant differentially expressed microRNAs among imatinib-treated and non-treated groups were identified using SAM analysis. Agilent microarray platform with probes matching 903 human microRNAs was used to determine miRNA expression profiles in 34 GISTs (19 imatinib-treated and 15 non-treated). Re-analysis of GSE45901 for 17 imatinib-treated GISTs. To validate the microarray platform, the expression levels of selected microRNAs were evaluated using qRT-PCR.

2015-08-01 | E-GEOD-63159 | biostudies-arrayexpress

Small RNA expression signatures of gastrointestinal stromal tumors: associations to imatinib resistance and patient outcome

Project description:We performed miRNA expression profiling in a series of fresh-frozen neoadjuvantly imatinib treated gastrointestinal stromal tumors (GIST), using a microarray approach. Significant differentially expressed miRNAs among imatinib-resistant and imatinib-sensitive groups were identified using SAM analysis. Agilent microarray platform with probes matching 903 human miRNAs was used to determine miRNA expression profiles in 17 GISTs (imatinib-sensitive and 7 imatinib-resistant). To validate the microarray platform, the expression levels of selected miRNAs were evaluated using qRT-PCR.

2013-04-10 | E-GEOD-45901 | biostudies-arrayexpress

Novel treatment of human pancreatic cancer using masitinib combined with standard gemcitabine chemotherapy

Project description:Masitinib is a tyrosine kinase inhibitor of c-Kit, PDGFRα and β, and to some extent Lyn of the Src kinase family. We evaluated the therapeutic potential of masitinib in vitro on human pancreatic tumour cell lines and in vivo in a mouse model of human pancreatic cancer.

2009-09-05 | GSE17987 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data